These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1109 related articles for article (PubMed ID: 16807131)

  • 21. Evaluation of underlying risk as a source of heterogeneity in meta-analyses: a simulation study of Bayesian and frequentist implementations of three models.
    Dohoo I; Stryhn H; Sanchez J
    Prev Vet Med; 2007 Sep; 81(1-3):38-55. PubMed ID: 17477995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inference methods for saturated models in longitudinal clinical trials with incomplete binary data.
    Song JX
    Pharm Stat; 2006; 5(4):295-304. PubMed ID: 17128429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of method comparison studies.
    Williamson PR; Lancaster GA; Craig JV; Smyth RL
    Stat Med; 2002 Jul; 21(14):2013-25. PubMed ID: 12111884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weibull prediction of event times in clinical trials.
    Ying GS; Heitjan DF
    Pharm Stat; 2008; 7(2):107-20. PubMed ID: 17377932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes.
    Hu M; Cappelleri JC; Lan KK
    Clin Trials; 2007; 4(4):329-40. PubMed ID: 17848494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empirical evaluation showed that the Copas selection model provided a useful summary in 80% of meta-analyses.
    Carpenter JR; Schwarzer G; Rücker G; Künstler R
    J Clin Epidemiol; 2009 Jun; 62(6):624-631.e4. PubMed ID: 19282148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel.
    Dansirikul C; Choi M; Duffull SB
    Comput Biol Med; 2005 Jun; 35(5):389-403. PubMed ID: 15767115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
    Gomeni R; Lavergne A; Merlo-Pich E
    Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation.
    Thiessen Philbrook H; Barrowman N; Garg AX
    J Clin Epidemiol; 2007 Mar; 60(3):228-40. PubMed ID: 17292016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confidence intervals for the overall effect size in random-effects meta-analysis.
    Sánchez-Meca J; Marín-Martínez F
    Psychol Methods; 2008 Mar; 13(1):31-48. PubMed ID: 18331152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Confidence intervals for the amount of heterogeneity in meta-analysis.
    Viechtbauer W
    Stat Med; 2007 Jan; 26(1):37-52. PubMed ID: 16463355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the proportion of studies missing for meta-analysis due to publication bias.
    Formann AK
    Contemp Clin Trials; 2008 Sep; 29(5):732-9. PubMed ID: 18586577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imputation strategies for blood pressure data nonignorably missing due to medication use.
    Cook NR
    Clin Trials; 2006; 3(5):411-20. PubMed ID: 17060215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Meta-analysis of therapeutic and preventive clinical trials].
    Lugosi L; Molnár I
    Orv Hetil; 2000 Dec; 141(51):2779-84. PubMed ID: 11196238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing treatment effects in unconfounded studies under model misspecification: logistic regression, discretization, and their combination.
    Cangul MZ; Chretien YR; Gutman R; Rubin DB
    Stat Med; 2009 Sep; 28(20):2531-51. PubMed ID: 19572258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesizer 1.0: a varying-coefficient meta-analytic tool.
    Krizan Z
    Behav Res Methods; 2010 Aug; 42(3):863-70. PubMed ID: 20805608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?
    Huedo-Medina TB; Sánchez-Meca J; Marín-Martínez F; Botella J
    Psychol Methods; 2006 Jun; 11(2):193-206. PubMed ID: 16784338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weighted nonparametric maximum likelihood estimate of a mixing distribution in nonrandomized clinical trials.
    Liu C; Xie J; Zhang Y
    Stat Med; 2007 Dec; 26(29):5303-19. PubMed ID: 17497612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SCEW: a Microsoft Excel add-in for easy creation of survival curves.
    Khan HA
    Comput Methods Programs Biomed; 2006 Jul; 83(1):12-7. PubMed ID: 16777258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.